Genus plc (GNSN) AI Stock Analysis
Genus plc
(BMV:GNSN)
No summary available
Genus plc Business Overview & Revenue Model
Company Description
Genus plc is a global animal genetics company with operations spanning North America, Latin America, the UK, continental Europe, the Middle East, Russia, Africa, and Asia. The business is divided into three key segments: Genus PIC, Genus ABS, and Gen...
Genus plc Earnings Call Summary
The call was strongly positive overall. Management reported substantial adjusted profit, EPS, free cash flow, margin, leverage, and return-on-capital improvements, alongside strong PIC China and ABS performance, PRP regulatory progress, capital returns, and a moderately higher FY 2027 profit outlook. These strengths were partly offset by disease pressure in North America, weak pork and dairy market conditions, expected moderation in Brazil and lower FY 2027 free cash flow, but the stated outlook remained for resilient underlying growth.
Q4-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For FY 2027, the Group expects underlying adjusted PBT constant currency to be moderately higher year on year, in line with consensus expectations, with moderate adjusted operating profit growth for both PIC from a normalized base and ABS; Group PBT is expected to be second half weighted, with FY 2027 phasing a very similar flip around to FY 2026, where more than 50% was in the first half. FY 2027 free cash flow is expected to also be strong but lower than FY 2026, principally due to the China joint venture formation and a modest increase in net capital expenditure; research costs are expected to grow in FY 2027 albeit remaining below 3% of group revenue, underlying PRP costs are expected to increase further, and the VAP program is targeted to complete during the first half of FY 27. The FY 2027 tax rate is expected to be broadly similar to 27.2%, leverage is expected to be around the bottom end of the targeted range of 1 to 2 times, Brazil is probably going to see lower growth in FY 2027, and North America could see a return to growth in the second half of FY 2027 if there is more normalization.
Genus plc Peers Comparison
Overall Rating
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.